Cited by 222Glioma Diagnosis and TreatmentAcute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

Kloosterhof, Nanne K, Bralten, Linda BC, Dubbink, Hendrikus J, French, Pim J, van den Bent, Martin J·2011·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70053-x

Open this paper in CoChat — free account

Abstract

The discovery of somatic mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) in glioblastomas was remarkable because the enzyme was not previously identified with any known oncogenic pathway. IDH1 is mutated in up to 75% of grade II and grade III diffuse gliomas. Apart from acute myeloid leukaemia, other tumour types do not carry IDH1 mutations. Mutations in a homologous gene, IDH2, have also been identified, although they are much rarer. Although TP53 mutations and 1p/19q codeletions are mutually exclusive in gliomas, in both of these genotypes IDH1 mutations are common. IDH1 and IDH2 mutations are early events in the development of gliomas. Moreover, IDH1 and IDH2 mutations are a major prognostic marker for overall and progression-free survival in grade II-IV gliomas. Mutated IDH1 has an altered catalytic activity that results in the accumulation of 2-hydroxyglutarate. Molecularly, IDH1 and IDH2 mutations are heterozygous, affect only a single codon, and rarely occur together. Because IDH1 does not belong to a traditional oncogenic pathway and is specifically and commonly mutated in gliomas, the altered enzymatic activity of IDH1 may provide a fundamentally new understanding of diffuse glioma.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70053-x

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global cancer statistics
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
The Biology of Cancer
Weinberg, R. A., & Weinberg, R. A. (2006) · W.W. Norton eBooks · doi:10.1201/9780203852569 · Cited by 1,806

Show all 86 references

Research works printed but not linked: 1

Yan, 2009, IDH1 and IDH2 mutations play a fundamental role in glioma development, Neuro Oncol, 11, 608

Sorted by citations

Items 101–200 of 222

The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China
Shen, G., Wang, R., Gao, B., Zhang, Z., Wu, G., & Pope, W. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00852 · Cited by 20
Mouse Models of Experimental Glioblastoma
Jin, F., Jin‐Lee, H. J., & Johnson, A. J. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.gliomas.2021.chapter2 · Cited by 18
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein
Ikota, H., Nobusawa, S., Tanaka, Y., Yokoo, H., & Nakazato, Y. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-010-0016-y · Cited by 19
The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
Vidmar, M. S., Doma, A., Smrdel, U., Zevnik, K., & Studen, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126787 · Cited by 18
Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients
Priambada, D., Arifin, M. T., Saputro, A., Muzakka, A. T. E., Karlowee, V., Sadhana, U., Bakhtiar, Y., Prihastomo, K. T., Risdianto, A., Brotoarianto, H. K., et al. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s397550 · Cited by 18
MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas
Mikkelsen, V. E., Dai, H. Y., Stensjøen, A. L., Berntsen, E. M., Salvesen, Ø. O., Solheim, O. S., & TORP, S. H. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa060 · Cited by 18
Metabolic network modeling approaches for investigating the “hungry cancer”
Sharma, A. K., & König, R. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.05.001 · Cited by 17
Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma
Chen, Y., Ho, H., Lin, S., Hsu, C., & Ho, D. M. (2018) · Neurosurgery · doi:10.1093/neuros/nyy338 · Cited by 17
Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis
He, X., Liao, Y.-D., Guo, X. Q., Wang, R., Xiao, Z., & Wang, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9140-3 · Cited by 17
Multifocal intracranial astrocytoma in a pediatric patient with Ollier disease
Bathla, G., Gupta, S., & Ong, C. K. (2012) · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · doi:10.4103/0971-3026.95406 · Cited by 17
Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence
Sabit, H., Nakada, M., Furuta, T., Watanabe, T., Hayashi, Y., Sato, H., Kato, Y., & Hamada, J.-I. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-013-0172-y · Cited by 16
Role of isocitrate dehydrogenase in glioma
Alexander, B. M., & Mehta, M. P. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.134 · Cited by 16
Novel ways to target brain tumour metabolism
Stieber, D., Rahim, S. A. A., & Niclou, S. P. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.588211 · Cited by 17
Protective role of cytosolic NADP+-dependent isocitrate dehydrogenase, IDH1, in ischemic pre-conditioned kidney in mice
Kim, J., Kim, J. I., Jang, H., Park, J., & Park, K. M. (2011) · Free Radical Research · doi:10.3109/10715762.2011.577426 · Cited by 16
Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population
Malueka, R. G., Dwianingsih, E. K., Bayuangga, H. F., Panggabean, A. S., Argo, I. W., Donurizki, A. D., Shaleh, S., Wicaksono, A. S., Dananjoyo, K., Asmedi, A., et al. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.8.2287 · Cited by 16
Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers
Jadoon, S. S., Ilyas, U., Zafar, H., Paiva‐Santos, A. C., Khan, S., Khan, S. A., Ahmed, T., Rasool, Y., Altaf, R., Raza, F., et al. (2022) · Journal of Oncology · doi:10.1155/2022/4022960 · Cited by 15
Can metabolic plasticity be a cause for cancer? Warburg–Waddington legacy revisited
Bhat, P. J., Darunte, L. A., Kareenhalli, V. V., Dandekar, J. U., & Kumar, A. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0030-x · Cited by 16
Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models
Chow, L. M. L., & Baker, S. J. (2012) · Oncotarget · doi:10.18632/oncotarget.425 · Cited by 15
Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas
Bralten, L. B. C., Nouwens, S., Kockx, C. E. M., Erdem‐Eraslan, L., Hoogenraad, C. C., Kros, J. M., Moorhouse, M. J., Smitt, P. A. E. S., van der Spek, P. J., van IJcken, W. F. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022000 · Cited by 14
Self-citation
Overexpression of isocitrate dehydrogenase-1R132H enhances the proliferation of A172 glioma cells via aerobic glycolysis
Nie, Q., Pin, G., Guo, L., LAN, J., Lin, Y., Guo, F., Zhou, S., Ge, J., Mao, Q., LI, X., et al. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3187 · Cited by 14
DZIP3 is a key factor to stratify IDH1 wild-type lower-grade gliomas
Liang, T., Zhou, X., Li, P., You, G., Wang, F., Wang, P., & Feng, E. (2020) · Aging · doi:10.18632/aging.103817 · Cited by 13
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation
Mascelli, S., Raso, A., Biassoni, R., Severino, M., Sak, K., Joost, K., Milanaccio, C., Barra, S., Ruggieri, F. G., Vanni, I., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0925-1 · Cited by 13
Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients
Weenink, B., van Brakel, M., Wijers, R., Smitt, P. A. E. S., French, P. J., & Debets, R. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03228-6 · Cited by 13
Self-citation
Mitochondrial DNA mutations induce mitochondrial biogenesis and increase the tumorigenic potential of Hodgkin and Reed–Sternberg cells
Haumann, S., Boix, J., Knuever, J., Bieling, A. M., Vila‐Sanjurjo, A., Elson, J. L., Blakely, E. L., Taylor, R. W., Riet, N., Abken, H., et al. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa032 · Cited by 12
Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case
Nakhla, J. P., Gajavelli, S., Nasser, R., Yassari, R., Weidenheim, K. M., & Graber, J. J. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.189731 · Cited by 13
Redefining disease
Bell, J. I. (2010) · Clinical Medicine · doi:10.7861/clinmedicine.10-6-584 · Cited by 12
The novel BTB/POZ and zinc finger factor Zbtb45 is essential for proper glial differentiation of neural and oligodendrocyte progenitor cells
Södersten, E., Lilja, T., & Hermanson, O. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14154 · Cited by 12
Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping
Ishida, A., Shibuya, M., Komori, T., Nobusawa, S., Niimura, K., Matsuo, S., & Hori, T. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0098-9 · Cited by 12
Cancer of the Central Nervous System
Dorsey, J. F., Hollander, A. B., Alonso‐Basanta, M., Macyszyn, L., Bohman, L., Judy, K. D., Maity, A. M., Lee, J. Y. K., Lustig, R. A., Phillips∥, P. C., et al. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00066-7 · Cited by 12
Importancia de la mutación de la isocitrato deshidrogenasa tipo I como factor pronóstico en pacientes con glioblastomas y revisión de la literatura
de Quintana-Schmidt, C. J., Álvarez-Holzapfel, M. J., Nomdedeu, J. F., Bagué, S., Gallego, O. S., Leidinger, A., Salgado-López, L., & Molet, J. (2015) · Neurocirugía · doi:10.1016/j.neucir.2015.04.001 · Cited by 11
Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis
Wang, X., Li, X., Xu, F., Zhang, Y., Liu, H., & Tao, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9400-2 · Cited by 11
MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status
Li, G., Wang, Z., Zhang, C., Liu, X., Yang, F., Sun, L., Liang, J., Hu, H., Liu, Y., You, G., et al. (2018) · Disease Markers · doi:10.1155/2018/5975216 · Cited by 11
High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas
Willscher, E., Hopp, L., Kreuz, M., Schmidt, M., Hakobyan, S., Arakelyan, A., Hentschel, B., Jones, D., Pfister, S. M., Loeffler, M., et al. (2021) · Cancers · doi:10.3390/cancers13133198 · Cited by 11
The role of neuropathology in the management of progressive glioblastoma
Brat, D. J., Ryken, T. C., Kalkanis, S. N., & Olson, J. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1331-z · Cited by 11
The Role of Amide Proton Transfer (APT)-Weighted Imaging in Glioma: Assessment of Tumor Grading, Molecular Profile and Survival in Different Tumor Components
de Almeida, G. B., Pascuzzo, R., Mambrin, F., Aquino, D., Verri, M., Moscatelli, M. E. M., Bene, M. D., DiMeco, F., Silvani, A., Pollo, B., et al. (2024) · Cancers · doi:10.3390/cancers16173014 · Cited by 10
IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma
Deshmukh, S., Kelly, C. M., & Tinoco, G. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01115-3 · Cited by 15
Multi-omics data integration for subtype identification of Chinese lower-grade gliomas: A joint similarity network fusion approach
Li, L., Wei, Y., Shi, G., Yang, H., Li, Z., Fang, R., Cao, H., & Cui, Y. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.065 · Cited by 9
Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging
Liu, S., Zhang, Y., Kong, Z., Jiang, C., Wang, Y., Zhao, D., You, H., Ma, W., & Feng, F. (2022) · BMC Neuroscience · doi:10.1186/s12868-022-00750-8 · Cited by 9
Oxford and the Savannah: Can the Hippo Provide an Explanation for Peto's Paradox?
Kelleher, F. C., & O’Sullivan, H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2010 · Cited by 9
Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?
Scott, J. G., Basanta, D., Chinnaiyan, P., Canoll, P., Swanson, K. R., & Anderson, A. R. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor083 · Cited by 9
Estudio de mutaciones en los genes IDH1 e IDH2 en una muestra de gliomas de población colombiana
Ricaurte, O., Neita, K., Valero, D., Ortega-Rojas, J., Bustos, C., Zubieta, C., Penagos, J., & Arboleda, G. (2017) · Biomédica · doi:10.7705/biomedica.v38i0.3708 · Cited by 9
Genetic and Epigenetic Alterations in Primary–Progressive Paired Oligodendroglial Tumors
Kuo, L., Tsai, S., Chang, C., Kuo, K., Huang, A. P., Tsai, J., Tseng, H.-M., Kuo, M., & Tu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067139 · Cited by 8
Histopathologic Features in Relation to Pretreatment Tumor Growth in Patients with Glioblastoma
Mikkelsen, V. E., Stensjøen, A. L., Berntsen, E. M., Nordrum, I. S., Salvesen, Ø. O., Solheim, O. S., & TORP, S. H. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.09.102 · Cited by 8
Reappraising the 2016 WHO classification for diffuse glioma
Lin, A. L., & DeAngelis, L. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox003 · Cited by 8
Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity
Tu, Y., & Li, Q. (2015) · Cancer translational medicine · doi:10.4103/2395-3977.168573 · Cited by 7
Potential of sonobiopsy as a novel diagnosis tool for brain cancer
Li, Y., Fu, K., Li, L., Li, Q., & Zhou, X. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200840 · Cited by 7
Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma
Shayanfar, N., Zare‐Mirzaie, A., Mohammadpour, M., Jafari, E., Mehrtash, A., Emtiazi, N., & Tajik, F. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04336-z · Cited by 8
New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status
Shibahara, I., Sonoda, Y., Kanamori, M., Saito, R., Kumabe, T., & Tominaga, T. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-011-0050-4 · Cited by 7
Magnetic Resonance Metabolic Imaging of Glioma
Métellus, P., & Figarella-Branger, D. F. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003591 · Cited by 7
Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1
Kim, H.-J., Choi, B. Y., & Keum, Y. (2015) · Journal of Cancer Prevention · doi:10.15430/jcp.2015.20.1.78 · Cited by 7
Comparison of Polymerase Chain Reaction–Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas
Malueka, R. G., Theresia, E., Fitria, F., Argo, I. W., Donurizki, A. D., Shaleh, S., Innayah, M. R., Wicaksono, A. S., Dananjoyo, K., Asmedi, A., et al. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.11.3229 · Cited by 7
Novel Magnetic Resonance Imaging and Positron Emission Tomography in the RT Planning and Assessment of Response of Malignant Gliomas
Kamson, D. O., & Tsien, C. I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00078-8 · Cited by 6
Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas
Huang, T., Li, S., Yang, Z., Liu, J., & Han, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9523-5 · Cited by 6
Association between MTHFR 677C>T polymorphism and risk of gliomas: evidence from a meta-analysis
Lu, Q., Dai, D., Zhao, W., Wang, L., Yue, Z., Chen, X., Han, G., Hao, B., Yang, P., Deng, A., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-0838-4 · Cited by 6
Anaplastic oligodendroglial tumors
van den Bent, M. J., & Bromberg, J. E. C. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53502-3.00003-3 · Cited by 6
Construction of ceRNA networks with different types of IDH1 mutation status in low-grade glioma patients
Wang, W., Lu, Y., Li, Y., Tang, J., Wang, H., Song, W., Wang, J., Huang, Y., Wang, Y., & Lian, L. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6983 · Cited by 5
Molecular Pathology of the Central Nervous System
Harris, B. T., & Hattab, E. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4900-3_16 · Cited by 5
Concomitant KIAA1549-BRAF fusion and IDH mutation in Pediatric spinal cord astrocytoma: a case report and literature review
Sun, M., Wang, L., Lu, D., Zhao, Z., Teng, L., Wang, W., & Piao, Y. (2021) · Brain Tumor Pathology · doi:10.1007/s10014-021-00394-2 · Cited by 5
MicroRNA-575 acts as a novel oncogene via targeting multiple signaling pathways in glioblastoma
Gray, A., Cui, T., Bell, E. H., McElroy, J., Sebastian, E., Li, F., Geurts, M., Liu, K., Robe, P. A. J. T., Haque, S. J., et al. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104813 · Cited by 5
Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
Kenshi, S. A. N. O., Matsuda, K., Kawanami, K., Kanemura, Y., Ohe, R., & Sonoda, Y. (2021) · NMC Case Report Journal · doi:10.2176/nmccrj.cr.2020-0151 · Cited by 5
MRI during radiotherapy of glioblastoma
Leitzen, C., Wilhelm-Buchstab, T. M., Schmeel, L. C., Garbe, S., Greschus, S., Müdder, T., Oberste-Beulmann, S., Simon, B., Schild, H. H., & Schüller, H. (2016) · Strahlentherapie und Onkologie · doi:10.1007/s00066-016-0983-y · Cited by 5
Mitochondrial complex I subunit NDUFS4 overexpression drives glioma progression by regulating mitochondrial function and COX5B
Wu, J., Li, J., Li, X., Liu, Y., & Jiang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01281-9 · Cited by 4
Current and emerging therapies in IDH-mutant glioma
Nakhate, V., Youssef, G., & Wen, P. Y. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00913 · Cited by 5
Oncology Scan—Low-Grade Gliomas: Predicting and Changing Outcome
Kirkpatrick, J. P. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.009 · Cited by 4
Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening
Shin, K., Shin, H., Cho, H. J., Kang, H., Lee, J., Seo, Y. J., Shin, Y. J., Kim, D., Koo, H., Kong, D., et al. (2020) · Cancers · doi:10.3390/cancers12030549 · Cited by 4
Signaling Cascades Driving the Malignant Phenotype of Glioma Cells
Nakada, M., Kita, D., Furuta, T., Watanabe, T., Hayashi, Y., & Hamada, J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1431-5_3 · Cited by 4
The Role of mTOR Signaling in Tumor-Induced Alterations to Neuronal Function in Diffusely Infiltrating Glioma
Haile, H., Leskinen, S., Adapa, A. R., Goldberg, A. R., Viswanathan, A., Milligan, C., Conboy, K., Schevon, C. A., Canoll, P., & Gill, B. J. A. (2025) · Biomedicines · doi:10.3390/biomedicines13112593 · Cited by 3
Joint application of biochemical markers and imaging techniques in the accurate and early detection of glioblastoma
Jafari, S. H., Rabiei, N., Taghizadieh, M., Mirazimi, S. M. A., Kowsari, H., Farzin, M. A., Bahabadi, Z. R., Rezaei, S., Mohammadi, A. H., Alirezaei, Z., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153528 · Cited by 3
An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas
Xiao, G., Gao, X., Li, L., Liu, C., Liu, Z., Peng, H., Xia, X., Yi, X., & Zhou, R. (2021) · Journal of Oncology · doi:10.1155/2021/3766685 · Cited by 3
“The simplest explanation is usually the correct one” – Can Occam’s razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?
Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3708-2 · Cited by 3
HOT mutation screening in human glioblastomas
Krell, D., Mulholland, P. J., Stebbing, J., Tomlinson, I. P. M., & Bardella, C. (2015) · Future Science OA · doi:10.4155/fso.15.20 · Cited by 2
Malignant glioma in L-2-Hydroxy Glutaric Aciduria: thorough molecular characterization of a case and literature review
Cordier, F., Wesseling, P., Tops, B. B. J., Kester, L. A., French, P. J., van den Bent, M. J., Hinz, F. E., Aronica, E., Slot, K.-A. M., Abbink, F. C. H., et al. (2024) · Free Neuropathology · doi:10.17879/freeneuropathology-2024-5377 · Cited by 2
Self-citation
Molecular landscape of glucose metabolism in glioblastoma and the normal human brain: A narrative review
Shah, P., Pallavali, R. R., & Guda, D. R. (2024) · Glioma · doi:10.4103/glioma.glioma_2_24 · Cited by 3
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review)
Yu, L., & Qi, S. (2011) · Oncology Letters · doi:10.3892/ol.2011.447 · Cited by 2
Tissue-Specific Functions of p53 During Kidney Development
Saifudeen, Z. R. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-51436-9_5 · Cited by 2
IDH1 Mutation in Gliomas in Baghdad by Immunohistochemical Study
Shaban, Z. M. (2018) · International Journal of Genetics and Genomics · doi:10.11648/j.ijgg.20180601.11 · Cited by 2
Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas
Smrdel, U., Smrdel, A. C. Š., Podlešek, A., Vidmar, M. S., Kos, G., Markovic, J., Jereb, J., Knific, J., & Rus, T. (2023) · Croatian Medical Journal · doi:10.3325/cmj.2023.64.383 · Cited by 2
Immunohistochemical analysis of IDH1, ATRX, p53, and Ki-67 in glioblastoma and diffuse infiltrative glioma: Therapeutic and prognostic correlation
Hasbay, B., Kayaselçuk, F., Süner, H. İ., & Tufan, K. (2025) · Vojnosanitetski pregled · doi:10.2298/vsp241008042h · Cited by 1
Epigenetic Alterations in Glioblastoma Multiforme
Wiencke, J. K. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3345-3_4 · Cited by 1
BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER
Field, K. M., & Rosenthal, M. A. (2015) · Cancer Forum · Cited by 1
Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas Benjamin EllezamBrett J. TheelerTobias WalbertAaron G. Mammoser • Craig HorbinskiBette K. Kleinschmidt-DeMastersArie Perry • Vinay PuduvalliGregory N. FullerJanet M. BrunerKenneth D. Aldape
Ellezam, B., Fuller, G. N., Bruner, J. M., Aldape, K., Theeler, B. J., Walbert, T., Mammoser, A. G., Puduvalli, V. K., Horbinski, C., Kleinschmidt-DeMasters, B. K., et al. (2012) · Cited by 1
Oligodendroglial Tumors
Yip, S. S. F., & Blakeley, J. O. (2014) · Molecular pathology library · doi:10.1007/978-1-4939-1830-0_8 · Cited by 1
Tumors of the Glia: Recent Advances
Suri, V. S., Mahajan, S., Singh, J., Dandapath, I., Chakraborty, R., Khan, A., Sharma, M. C., & Sarkar, C. (2022) · Springer eBooks · doi:10.1007/978-981-16-8313-8_13 · Cited by 1
Molecular Subtypes of Gliomas
Gravendeel, L. A. M., & French, P. J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0618-7_3 · Cited by 1
Self-citation
IDH1 mutation decreases the invasiveness of glioma by downregulating the expression and activity of TAZ
Liu, Y., Li, N., Zhang, R., Sun, Y., Xu, C., Wang, Y., Xiong, J., & Chen, Q. (2019) · Glioma · doi:10.4103/glioma.glioma_46_18 · Cited by 1
Glioblastoma Drug Treatments and Animal Models
Yıldız, E. (2021) · Journal of Experimental and Basic Medical Sciences · doi:10.5606/jebms.2020.75630 · Cited by 1
MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma
Alfardus, H., McIntyre, A., & Smith, S. J. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pabs.1.2020.7 · Cited by 1
Immunohistochemistry and Brain Tumors
Takei, H., Powell, S. Z.-E., & Rivera, A. L. (2014) · Encyclopedia of the Neurological Sciences · doi:10.1016/b978-0-12-385157-4.00592-3 · Cited by 1
Nuevas aportaciones a la caracterización molecular de los gliomas
Hernández, I. R. (2013) · Gredos (University of Salamanca) · doi:10.14201/gredos.123043
Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma
Ohgaki, H. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2213-5_5 · Cited by 1
MicroRNA-183 upregulates HIF-1a by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
TanakaTakashi, H., & NishiharaKatsu, M. (2013)
ANALYSIS OF TUMOR SPECIFIC PROTEIN EXPRESSION IN GLIOBLASTOMA MULTIFORME (GBMs) TUMORS THROUGH IMMUNOHISTOCHEMISTRY
Wigand, A. M. (2016)
Stem Cell-Based Approaches for Treatment of Glioblastoma
Erkan, E. P., Eren, E., Genç, Ş., & Genc, K. K. (2017) · Stem cells in clinical applications · doi:10.1007/978-3-319-33720-3_4
Intracytoplasmic lipid droplets in high grade glioma : metabolism and target for therapy
Murren, R. (2018) · University of Birmingham Institutional Research Archive (University of Birmingham)
High-Grade Gliomas
Vlacich, G. R., & Tsien, C. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-42878-9_6
Different IDH Mutation and 1p/19q Codeletion Rates between Astrocytoma, Oligodendrocytoma and Mixed Gliomas
Sun, J., Wang, Z., Liu, Q., Huang, X., & Xu, Z. (2018) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000316
PERAN PENANDA MOLEKULER PADA TERAPI GLIOMA
Malueka, R. G., Yudiyanta, Y., & Asmedi, A. (2017) · Majalah Kedokteran Neurosains Perhimpunan Dokter Spesialis Saraf Indonesia · doi:10.52386/neurona.v35i1.40
Clinical presentation of spinal oligodendrogliomas
Pham, L. C., Cachia, D., Patel, A. J., & Mandel, J. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813158-9.00002-5
Computational genomics of brain tumors: identification and characterization of glioma candidate biomarkers through multi-omics integrative molecular profilingPreprint
Liu, L., Wang, G., Wang, L., Yu, C., Li, M., Song, S., Hao, L., Ma, L., & Zhang, Z. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/798785
Tissue thiol concentration in high-grade gliomas: is there any association between idh1 mutation presence and tumoral cellular antioxidant defense?
Evran, Ş., Kayhan, A., Baran, O., Çevik, S., Katar, S., Kaya, M., Sönmez, D., Serin, H., Hanımoğlu, H., & Kaynar, M. Y. (2020) · Turkish Neurosurgery · doi:10.5137/1019-5149.jtn.31866-20.2

Authors: Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J.
Affiliations: Erasmus MC - Sophia Children’s Hospital (NL)
Daniel den Hoed Kliniek (NL)
Erasmus MC (NL)
ORCID: Dubbink, Hendrikus J
French, Pim J
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2011-01
Volume: 12
Issue: 1
Pages: 83-91
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70053-x
OpenAlex: W2084945856
Cited by: 222
References: 86
Citations by year: 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 12 · 2021: 19 · 2020: 21 · 2019: 10 · 2018: 11 · 2017: 12 · 2016: 12 · 2015: 17 · 2014: 19 · 2013: 20 · 2012: 17
FWCI: 2.36
Type: journal article
Language: en
Update notices: erratum (2010-10-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: IDH1, IDH1 mutation, IDH2 mutation, diffuse glioma, glioblastoma, 2-hydroxyglutarate, TP53 mutation, 1p/19q codeletion, prognostic factors, tumor progression, oncogenic signaling
MeSH terms: Brain Neoplasms, Codon, Glioma, Humans, Isocitrate Dehydrogenase, Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks